International Journal of Molecular Medical Science, 2025, Vol.15, No.5, 224-234 http://medscipublisher.com/index.php/ijmms 2 33 Jin R., Liu C., Zheng S., Wang X., Feng X., Li H., Sun N., and He J., 2020, Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer, Cancer Biology and Medicine, 17: 768-781. https://doi.org/10.20892/j.issn.2095-3941.2020.0121 Kang J., Zhang C., and Zhong W., 2021, Neoadjuvant immunotherapy for non-small cell lung cancer: state of the art, Cancer Communications, 41: 287-302. https://doi.org/10.1002/cac2.12153 Li X., Yan S., Yang J., Wang Y., LüC., Li S., Zhao J., Yang Y., Zhuo M., and Wu N., 2021, Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a network analysis of randomized controlled trials, Frontiers in Oncology, 10: 574752. https://doi.org/10.3389/fonc.2020.574752 Li Z., Yan H., Gu J., Yang Y., Fang X., and Zhang M., 2020, Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials, Pharmacological Research, 160: 105194. https://doi.org/10.1016/j.phrs.2020.105194 Liu L., Yan Y., Wang Y., Li Z., Yang L., Yu K., and Zhao Z., 2025, Comparative efficacy and safety of first-line PD-1/PD-L1 inhibitors in immunotherapy for non‑small cell lung cancer: a network meta-analysis, Oncology Letters, 29(3): 157. https://doi.org/10.3892/ol.2025.14903 Liu X.P., and Zhang J., 2025, Survival benefit analysis of PD-1/PD-L1 inhibitors in non-small cell lung cancer, Cancer Genetics and Epigenetics 13(4): 184-193 https://doi.org/10.5376/cge.2025.13.0019 Majem M., Cobo M., Isla D., Márquez-Medina D., Rodríguez-Abreu D., Casal-Rubio J., Bueno T., Bernabé-Caro R., Parente D., Ruiz-Gracia P., Arroyo M., and Paz-Ares L., 2021, PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high pd-l1 expression: a network meta-analysis, Journal of Clinical Medicine, 10(7): 1365. https://doi.org/10.3390/jcm10071365 Molina J., Yang P., Cassivi S., Schild S., and Adjei A., 2008, Non-small cell lung cancer: epidemiology risk factors treatment and survivorship, Mayo Clinic Proceedings, 83(5): 584-594. https://doi.org/10.4065/83.5.584 Qu J., Mei Q., Liu L., Cheng T., Wang P., Chen L., and Zhou J., 2021, The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer, Therapeutic Advances in Medical Oncology, 13: 1758835921992968. https://doi.org/10.1177/1758835921992968 Rodak O., Peris-Díaz M., Olbromski M., Podhorska-Okołów M., and Dzięgiel P., 2021, Current landscape of non-small cell lung cancer: epidemiology histological classification targeted therapies and immunotherapy, Cancers, 13(18): 4705. https://doi.org/10.3390/cancers13184705 Shankar B., Zhang J., Naqash A., Forde P., Feliciano J., Marrone K., Ettinger D., Hann C., Brahmer J., Ricciuti B., Owen D., Toi Y., Walker P., Otterson G., Patel S., Sugawara S., and Naidoo J., 2020, Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer, JAMA oncology, 6(12): 1952-1956. https://doi.org/10.1001/jamaoncol.2020.5012 Takada K., Takamori S., Mizuki F., Miura N., Shikada Y., and Shimokawa M., 2024, Treatment-related adverse events of combination chemoimmunotherapy versus chemotherapy alone in first-line treatment for non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials, Journal of Thoracic Disease, 16: 430-438. https://doi.org/10.21037/jtd-23-1532 Tang S., Qin C., Hu H., Liu T., He Y., Guo H., Yan H., Zhang J., Tang S., and Zhou H., 2022, Immune checkpoint inhibitors in non-small cell lung cancer: progress challenges and prospects, Cells, 11(3): 320. https://doi.org/10.3390/cells11030320 Wang M., Liang H., Wang W., Zhao S., Cai X., Zhao Y., Li C., Cheng B., Xiong S., Li J., He J., and Liang W., 2020, Immune-related adverse events of a PD‐ L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: a meta-analysis of randomized control trials, Cancer, 127(5): 777-786. https://doi.org/10.1002/cncr.33270 Wankhede D., Hofman P., and Grover S., 2022, PD-1/PD-L1 inhibitors in treatment-naïve advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials, Journal of Cancer Research and Clinical Oncology, 149: 2179-2189. https://doi.org/10.1007/s00432-022-04286-6 Wang L.T., 2025, Study on the application of targeted therapy combined with chemotherapy in cervical cancer patients, International Journal of Clinical Case Reports, 15(3): 139-147. https://doi.org/10.5376/ijccr.2025.15.0015 Yang Y., Cao L., Xu X., Li D., Deng Y., Li L., Zeng B., Jiang H., Shan L., Huang Y., Xu Y., and Ma L., 2025, NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer, Cancer Immunology Immunotherapy, 74(4): 132. https://doi.org/10.1007/s00262-025-03986-5 Zhang S., Bai X., and Shan F., 2020, The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer, International immunopharmacology, 80: 106247. https://doi.org/10.1016/j.intimp.2020.106247
RkJQdWJsaXNoZXIy MjQ4ODYzNA==